Page 41 - Recursion Pharmaceuticals News Today

Altitude Lab, one of the biggest healthcare startups in Utah recently announced that they just raised the largest volume of seed capital in history.

/PRNewswire/ -- The "AI-based Drug Discovery Market: Distribution by Drug Discovery Steps, Therapeutic Area and Key Geographies: Industry Trends and Global...

Every organism is born with a few mutations in their genome that differ genetically from both of their parents.

/PRNewswire/ -- The "AI In Pharma Global Market Report 2022, By Technology, Drug Type, Application" report has been added to ResearchAndMarkets.coms offering....

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

This March, Utah Business and Altitude Labs hosted a half-day summit on all things deep tech. In this panel, six female tech leaders discuss leadership and career growth.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

The hope is that AI can solve the single most challenging problem at the heart of modern drug discovery: the reliable prediction of novel small...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 37,155 shares of the firm’s stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $6.31, for a total value of $234,448.05. Following the sale, the chief executive officer now directly owns 420,146 shares in the company, […]

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) have received an average recommendation of “Hold” from the seven research firms that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month target […]